SENL101 / Avalon GloboCare  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SENL101 / SenlangBio
NCT04928105: Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
Lymphoma, T-Cell
01/23
03/23
NCT04916860: Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Active, not recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
01/23
03/23
NCT04938115: Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Completed
N/A
50
RoW
CD7 CART
Hebei Senlang Biotechnology Inc., Ltd.
Leukemia, T Cell
05/23
10/23
NCT05626400: Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
T-cell Acute Lymphoblastic Leukemia/Lymphoma
10/27
12/27

Download Options